BioStem Life Sciences, Inc., Subsidiary of BioStem Technologies, Inc., Announces Entry into Market with Four Amniotic Products
Pompano Beach, FL, Oct. 01, 2018 (GLOBE NEWSWIRE) -- BioStem Life Sciences (“Life Sciences” or the “Company”), a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), a Company focused on the development of the highest quality placental-based amniotic tissue products, whose mission is to create a new paradigm of healthcare, using breakthrough therapies that treat patients who otherwise are without effective treatment options, announced today that it has entered the market with four placental-derived tissue products for multiple indications within the ophthalmology, orthopedic and advanced wound care markets.
The four products are specifically an amniotic tissue allograft flowable matrix, a chorion-free amniotic tissue allograft membrane, an amniotic tissue allograft membrane with chorion layer, and an extracellular amniotic membrane allograft for ocular repair. Initial sales have already been established during Q3 2018. This entry into the $812 million amniotic tissue market poises the company for exponential growth in the near-term. In support of these product launches, the Company is currently introducing the new product offerings to nationwide distribution channels.
Placental tissue has proven to be a very powerful, versatile and safe allograft therapy in a wide range of pathologies treated in the regenerative medicine arena. The human amnion is a single layer of epithelial cells separating the amniotic cavity from the vascularized chorion. Amniotic Membrane has been shown to have the unique properties including the ability to suppress pain, fibrosis, and bacterial growth, as well as to promote wound healing.
BioStem Life Sciences President, Dr. Bruce Werber, stated, “…in my 35 years of practice, I have never had any tool or therapy, that comes close to the tremendous success and lack of adverse events as I have experienced with utilizing placental allograft to treat wounds and orthopedic conditions.”
About BioStem Life Sciences, Inc.: A company focused on the development of the highest quality placental-based amniotic tissue products for the ophthalmology, orthopedic and wound care markets, whose mission is to create a new paradigm of healthcare, using breakthrough therapies that treat patients who otherwise without effective treatment options.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
 Sajeev, Suraj, and Garima Chandra. “Amniotic Membrane Market by Product (Cryopreserved Amniotic Membrane and Lyophilization Amniotic Membrane), Application (Surgical Wounds, Ophthalmology and Others), and End User (Hospitals, Ambulatory Surgical Centers, Specialized Clinics, and Research Centers & Laboratory) - Global Opportunity Analysis and Industry Forecast, 2017-2023.” Allied Market Research, Allied Market Research, Feb. 2018, www.alliedmarketresearch.com/amniotic-membrane-market.
 Werber B. Dehydrated Human Amnion/Chorion Graft Bioassay; Indications for Use in Regenerative Therapeutics. 2017
BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: email@example.com Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst firstname.lastname@example.org (954) 380-8342